Literature DB >> 16849662

Incidence of opportunistic and other infections in HIV-infected children in the HAART era.

Philimon Gona1, Russell B Van Dyke, Paige L Williams, Wayne M Dankner, Miriam C Chernoff, Sharon A Nachman, George R Seage.   

Abstract

CONTEXT: Combination anti-retroviral therapy or highly active antiretroviral therapy (HAART) has resulted in a dramatic decline in the incidence of opportunistic and other infections in human immunodeficiency virus (HIV)-infected adults and children.
OBJECTIVES: To estimate the incidence of 29 targeted opportunistic and other infections occurring in the era of HAART-between January 1, 2001, and December 31, 2004-in HIV-infected infants, children, and adolescents followed up in Pediatric AIDS Clinical Trials Group (PACTG) 219C; to compare incidence rates in the HAART era to those of the pre-HAART era; and to test for linear trends over time in the HAART era. DESIGN, SETTING, AND PARTICIPANTS: Ongoing, multicenter, prospective cohort study designed to examine long-term outcomes in HIV-infected children. The study population included 2767 children enrolled between September 15, 2000, and December 31, 2004, with information entered in the database up to August 1, 2005, when data analysis was conducted. The pre-HAART era comparison population included 3331 children enrolled in 13 PACTG protocols from October 1988 to August 1998. MAIN OUTCOME MEASURES: First occurrence of each of the 29 targeted infections.
RESULTS: Seventy-five percent of the children were enrolled in 2000 and 2001, 90% acquired HIV perinatally, 52% were girls, and 59% were black. The median age was 8.2 years (range, 6-13 years). The median duration of follow-up was 3.4 years. Overall, 553 first episodes of a specific infection occurred among 395 (14%) of the study participants. The number of events for the 4 most common first-time infections and their incidence rates (IRs) per 100 person-years were 123 bacterial pneumonia (IR, 2.15; 95% confidence interval [CI], 1.79-2.56), 77 herpes zoster (IR, 1.11; 95% CI, 0.88-1.39), 57 dermatophyte infections (IR, 0.88; 0.67-1.14), and 52 oral candidiasis (IR, 0.93; 95% CI, 0.70-1.22). Incidence rates of first bacteremia, Pneumocystis jeroveci pneumonia, disseminated Mycobacterium avium complex, lymphoid interstitial pneumonitis, systemic fungal infection, cytomegalovirus retinitis, and tuberculosis were all less than 0.50 per 100 person-years. There were no statistically significant linear trends in incidence for any of the 29 infections over the 4 calendar years. However, infection rates were significantly lower than those reported in the PACTG in the pre-HAART era. The pre-HAART IRs were as follows: for bacterial pneumonia, IR, 11.1; 95% CI, 10.3-12.0; bacteremia, IR, 3.3; 95% CI, 2.9-3.8; herpes zoster, IR, 2.9; 95% CI, 2.6-3.3; disseminated M avium complex, IR, 1.8; 95% CI, 1.5-2.1; P jeroveci, IR, 1.3; 95% CI, 1.1-1.6; oral candidiasis, IR, 1.2; 95% CI, 1.0-1.5; cytomegalovirus retinitis, IR, 0.5; 95% CI, 0.3-0.6; and tuberculosis, IR, 0.2; 95% CI, 0.1-0.4.
CONCLUSIONS: Opportunistic infections and other related infections are uncommon in children in the HAART era, and infection rates continue to be lower than those reported in the pre-HAART era. Continued surveillance is important to assess the long-term effect of HAART on the occurrence of opportunistic and other related infections in children.

Entities:  

Mesh:

Year:  2006        PMID: 16849662     DOI: 10.1001/jama.296.3.292

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  84 in total

1.  Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV.

Authors:  Marilyn J Crain; Miriam C Chernoff; James M Oleske; Susan B Brogly; Kathleen M Malee; Peggy R Borum; William A Meyer; Wendy G Mitchell; John H Moye; Heather M Ford-Chatterton; Russell B Van Dyke; George R Seage Iii
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Lower total and regional grey matter brain volumes in youth with perinatally-acquired HIV infection: Associations with HIV disease severity, substance use, and cognition.

Authors:  C Paula Lewis-de Los Angeles; Paige L Williams; Yanling Huo; Shirlene D Wang; Kristina A Uban; Megan M Herting; Kathleen Malee; Ram Yogev; John G Csernansky; Sharon Nichols; Russell B Van Dyke; Elizabeth R Sowell; Lei Wang
Journal:  Brain Behav Immun       Date:  2017-01-10       Impact factor: 7.217

Review 3.  The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.

Authors:  Shabir A Madhi; Marta C Nunes
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

4.  Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy.

Authors:  Gayatri Mirani; Paige L Williams; Miriam Chernoff; Mark J Abzug; Myron J Levin; George R Seage; James M Oleske; Murli U Purswani; Rohan Hazra; Shirley Traite; Bonnie Zimmer; Russell B Van Dyke
Journal:  Clin Infect Dis       Date:  2015-08-12       Impact factor: 9.079

5.  The Use of the Medical Dictionary for Regulatory Activities in the Identification of Mitochondrial Dysfunction in HIV-Infected Children.

Authors:  Miriam Chernoff; Heather Ford-Chatterton; Marilyn J Crain
Journal:  Case Studies Bus Ind Gov Stat       Date:  2012-10

6.  Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors.

Authors:  Warren A Andiman; Miriam C Chernoff; Charles Mitchell; Murli Purswani; James Oleske; Paige L Williams; Hans Spiegel; Phil Gona; George R Seage
Journal:  Pediatr Infect Dis J       Date:  2009-07       Impact factor: 2.129

7.  Opportunistic infections in HIV infected children.

Authors:  Dinesh Kaul
Journal:  Indian J Pediatr       Date:  2011-03-22       Impact factor: 1.967

8.  Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

Authors:  Paige L Williams; Miguel Marino; Kathleen Malee; Susan Brogly; Michael D Hughes; Lynne M Mofenson
Journal:  Pediatrics       Date:  2010-01-18       Impact factor: 7.124

9.  Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.

Authors:  Katherine Tassiopoulos; Paige L Williams; George R Seage; Marilyn Crain; James Oleske; John Farley
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

10.  Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era.

Authors:  Sharon A Nachman; Miriam Chernoff; Philimon Gona; Russell B Van Dyke; Wayne M Dankner; George R Seage; James Oleske; Paige L Williams
Journal:  Arch Pediatr Adolesc Med       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.